Compounds for treatment of anti-amyotrophinopathies
By discovering and using compounds that induce utrophin upregulation, such as biphenipiramine, Vifrapone, etc., the challenge of gene replacement therapy in existing anti-dystrophin treatment methods was solved, significantly improved muscle function and enriched treatment strategies.
Patent Information
- Application Number
- CN202380032731.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-21
- Filing Date
- 2023-02-20
- Publication Date
- 2024-11-15
AI Technical Summary
Existing anti-dystrophinopathy treatments have not yet fully cured the disease, and the challenge of large gene size, wide distribution and activation of immune responses based on dystrophin replacement therapy requires new alternative treatment strategies.
A series of compounds such as biphenipiramine, Vifrapone, amopiquant, chlorclomon, aperis, benoxate, hipamine and famotazole were found to induce upregulation of utrophin. Therefore, it is used to prevent and treat anti-dystrophin diseases. These compounds may be used alone or in combination with other known drugs for the manufacture of drugs for the treatment and prevention of anti-dystrophin diseases.
By inducing utrophin upregulation, muscle function is significantly improved, the expression of utrophin in muscle fibers is increased, the therapeutic effect of anti-dystrophin disease is improved, the induction of immune response is avoided, and the therapeutic library for anti-dystrophin disease is enriched.
Smart Images

Figure CN118973560A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to compounds useful for the treatment and / or prevention of dystrophinopathies, and in particular Duchenne muscular dystrophy. Background Art
[0002] Dystrophinopathy is an X-linked progressive hereditary muscle degenerative disease caused by the absence or deficiency of dystrophin (a myofibril protein). The severity of dystrophinopathy varies. Mild forms include painful cramps with myoglobinuria; while severe forms include progressive muscle diseases such as Duchenne or Becker muscular dystrophy when mainly affecting skeletal muscle, or dilated cardiomyopathy when mainly affecting the heart (Astejada et al., Reference Module in Biomedical Sciences, International Encyclopedia of Public Health, 2nd Edition, 2017, Volume 5, 183-192; Darras et al., 2000 Sep 5 [updated on 2018 Apr 26]. In: Editors Adam MP, Ardinger HH, Pagon RA, et al., Gene Reviews, [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021, PMID: 20301298).
[0003] Duchenne muscular dystrophy (DMD) affects one in every 5,000 male newborns and occurs when a mutation occurs in the gene that encodes the protein dystrophin. It is a progressive neuromuscular disease with clinical symptoms appearing at 2-3 years of age, loss of ambulation in the early teens, and death from respiratory insufficiency or heart failure in the following decade.
[0004] Becker muscular dystrophy (BMD) has similar symptoms to DMD, but skeletal muscle weakness develops later, with some patients retaining the ability to walk into their 30s. However, heart failure remains the most common cause of death in BMD patients. The average age of death is in the 40s.
[0005] DMD-associated dilated cardiomyopathy (DCM) is characterized by left ventricular dilatation and congestive heart failure, although there is usually no clinical evidence of skeletal muscle disease. Females who are heterozygous for DMD pathogenic variants are at increased risk for DCM. Heart failure typically develops between the ages of 20 and 40 in males and later in females.
[0006] The protein affected in these diseases, dystrophin, connects sarcolemmal actin filaments to basement membrane protein complexes via the dystrophin-associated protein complex (DAPC) to enable mechanotransduction, providing structural integrity to skeletal and cardiac muscle. In dystrophinopathies, the entire DAPC is lost from the sarcolemma, resulting in abnormal mechanotransduction in the muscle fiber.
[0007] Although the molecular mechanisms of dystrophinopathy have been extensively studied, there is still no treatment that can completely cure dystrophinopathy (Soblechero-Martín et al., Neuropathol Appl Neurobiol, 2021; 00: 1-13). Current standard treatment includes corticosteroids, such as prednisone or deflazacort, to delay disease progression. Due to the large size of the gene, the widespread distribution of skeletal muscle throughout the body, and the possibility of activating immune responses, protein or gene-based dystrophin replacement therapy is challenging.
[0008] Recently, upregulation of the utrophin protein has gained momentum as one of the most promising alternative therapeutic strategies for dystrophinopathies. Utrophin is a dystrophin-related protein and an autosomal homologue of dystrophin that can also bind to proteins of DAPC and functionally replace dystrophin. Increasing the levels of utrophin in dystrophin-deficient muscle fibers in mdx mice, by increasing the levels of sarcolemma-bound utrophin, led to a partial restoration of the function of the affected muscles. Moreover, due to its endogenous expression, utrophin overexpression does not induce any immune response in dystrophinopathies.
[0009] Recent studies based on high-throughput screening, such as in myoblasts, have allowed the identification of small molecules capable of inducing utrophin upregulation and thus rescuing muscle function, some of which are undergoing clinical trials (Soblechero-Martín et al., Neuropathol Appl Neurobiol, 2021; 00: 1-13; Verhaart et al., Nature Reviews Neurology 15, 373-386 (2019)).
[0010] The aim of the present invention is to identify more compounds capable of inducing utrophin upregulation, thereby enriching the arsenal of therapeutics against dystrophinopathies. Summary of the invention
[0011] The present inventors have surprisingly found a series of compounds which are capable of inducing upregulation of utrophin and which are therefore useful in the prevention and treatment of dystrophinopathies.
[0012] Therefore, in a first aspect, the present invention relates to a compound selected from Difenpiramide, Veliflapon, Amopyroquine, Cloricromen, Alpelisib, Benorilate, Xipamide, Famotizole and Altizide, or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of dystrophinopathy.
[0013] In a second aspect, the present invention relates to the use of a compound selected from biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment and / or prevention of dystrophinopathy.
[0014] In a third aspect, the present invention also relates to a method for treating and / or preventing dystrophinopathy in a subject, comprising administering to the subject a therapeutically effective amount of a compound selected from biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazine, or a pharmaceutically acceptable salt thereof.
[0015] In a fourth aspect, the present invention relates to a combination comprising two or more agents, the agent being selected from biphenylpyramide, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole, althiazide or a pharmaceutically acceptable salt thereof; ataluren, deflazacort, givinostat, pizuglanstat, ifetroban, vamorolone, idebenone, prednisone, prednisolone, 20-hydroxyecdysone, metformin and L-citrulline combination, MA-0211, tamoxifen, dextro epicatechin), exaluren, ARM-210, 2,6-disubstituted pyridazine-3(2H)-one, N-benzyl p-toluenesulfonamide, MP-101, MT-002, rimeporide, tetracosactide hexaacetate, elamipretide, KER-050, SRP-5051, TXA-127, PB-1023, pamrevlumab, eteplirsen, golodirsen, vitolarsen, casimersen, ATL-1102, NS-089, renadirsen, WVEN-531, fordadistrogenemovaparvovec, GNT-004, AAV1-follistatin viral vector vector), delandistrogene moxeparvovec, AT-702, AAVrh74-GALGT2, SGT-001, CAP-2003, CAP-1002; wherein at least one of the agents is selected from bifenthrin, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide, or a pharmaceutically acceptable salt thereof.
[0016] In a fifth aspect, the invention relates to a combination according to the fourth aspect of the invention for use in the treatment and / or prevention of a dystrophinopathies.
[0017] In a sixth aspect, the present invention relates to the use of a combination according to the fourth aspect of the invention for the manufacture of a medicament for the treatment and / or prevention of a dystrophinopathy.
[0018] In a seventh aspect, the invention relates to a method for treating and / or preventing a dystrophinopathy in a subject, comprising administering to said subject a therapeutically effective amount of a combination according to the fourth aspect of the invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The maximum single contraction force in response to electrical stimulation following treatment with the compounds of the invention is shown.
[0020] Figure 2 Tetanic contraction in response to electrical stimulation is demonstrated following treatment with compounds of the invention.
[0021] Figure 3 The tetanic index in response to electrical stimulation following treatment with the compounds of the invention is shown.
[0022] Figure 4 Increased utrophin expression in human DMD cultures of immortalized DMD patient-derived three-dimensional skeletal muscle tissue following treatment with compounds of the invention is demonstrated. DETAILED DESCRIPTION
[0023] As mentioned above, the present invention relates to a series of nine compounds which have been found to induce utrophin upregulation. These compounds are described in detail below.
[0024] Veliflapon (CAS 128253-31-6; https: / / pubchem.ncbi.nlm.nih.gov / compound / Veliflapon), also known as Bay-x-1005, is a compound of the following formula:
[0025]
[0026] Preferably, Vivrabond refers to the following stereoisomers:
[0027]
[0028] Viflapon has been used to treat acute coronary syndrome in patients with a history of unstable angina or myocardial infarction. The compound is commercially available, such as Sigma Aldrich (Ref. SML0411); it can also be synthesized using a suitable preparation method, such as the method disclosed in US 4970215.
[0029] Difenpiramide (CAS 51484-40-3; https: / / pubchem.ncbi.nlm.nih.gov / compound / Difenpiramide) is a compound of the following formula:
[0030]
[0031] The compound has been used to treat degenerative and inflammatory joint diseases, such as osteoarthritis or rheumatoid arthritis. The compound is commercially available, such as Smolecule (Ref. S526059). The compound can also be synthesized by condensing the carboxyl group of ofiphenyl-4-ylacetic acid (CAS 5728-52-9) with the amino group of 2-aminopyridine (CAS 504-29-0), both of which are also easily available, such as Sigma-Aldrich (Ref. 196487 and 09340, respectively). The compound can also be synthesized by the method disclosed in US 3868380 or Khullar, Asian J. Chem., Vol. 31, No. 3 (2019), 510-514.
[0032] Amopyroquine (CAS 550-81-2; https: / / pubchem.ncbi.nlm.nih.gov / compound / Amopyroquine); is a compound of the formula:
[0033]
[0034] The compound has been used as an antimalarial agent. The compound is commercially available, such as Smolecule (Ref. S518739); or can be synthesized using a suitable preparation method, such as the method disclosed in Nobles et al., Journal of Pharmaceutical Sciences, Volume 52, Issue 6, June 1963, Pages 600-601.
[0035] Clocromen (CAS 68206-94-0; https: / / pubchem.ncbi.nlm.nih.gov / compound / Cloricromen) is a compound of the formula:
[0036]
[0037] The compound has been used as an antithrombotic drug, especially for treating arterial thrombosis. The compound can be purchased from the market, such as Parchem (Ref. 28592); it can also be synthesized by a suitable preparation method, such as the method disclosed in US 4452811 A.
[0038] Alpelisib (CAS 1217486-61-7; https: / / pubchem.ncbi.nlm.nih.gov / compound / Alpelisib), also known as BYL-719, is a compound of the following formula:
[0039]
[0040] Preferably, Apellis refers to the following stereoisomers:
[0041]
[0042] Apellis has been used as an anti-tumor drug, especially for the treatment of metastatic breast cancer. The compound is commercially available, such as Abcr GmbH (Ref. AB337610); it can also be synthesized using a suitable preparation method, such as the method disclosed in US2010105711 A1.
[0043] Benorilate (CAS 5003-48-5; https: / / pubchem.ncbi.nlm.nih.gov / compound / Benorilate) is a compound of the formula:
[0044]
[0045] The compound has been used as an anti-inflammatory, antipyretic and analgesic agent. The compound is commercially available, such as Sigma-Aldrich (Ref. PH003407); it can also be synthesized using a suitable preparation method, such as the method disclosed in US Pat. No. 3,431,293.
[0046] Xipamide (CAS 14293-44-8; https: / / pubchem.ncbi.nlm.nih.gov / compound / 26618) is a compound of the following formula:
[0047]
[0048] The compound has been used as a diuretic for the treatment of edema and hypertension. The compound is commercially available, such as Parchem (Ref. 13928); it can also be synthesized using a suitable preparation method, such as the method disclosed in US 3567777.
[0049] Famotizole (CAS 173352-21-1; https: / / pubchem.ncbi.nlm.nih.gov / compound / Fabomotizole), also known as Afobazole, is a compound of the following formula:
[0050]
[0051] The compound has been used as an antianxiety drug. The compound can be purchased from the market, such as Parchem (Ref. 110780); or it can be synthesized using a suitable preparation method, such as the method disclosed in US6376666 B1.
[0052] Althiazide (CAS 5588-16-9; https: / / pubchem.ncbi.nlm.nih.gov / compound / Althiazide) is a compound of the formula:
[0053]
[0054] Preferably, althiazine refers to the following stereoisomers:
[0055]
[0056] Althiazide has been used as a diuretic for the treatment of edema, hypertension and hormonal disorders. The compound is commercially available, such as Sigma-Aldrich (Ref. Y0000606); it can also be synthesized using a suitable preparation method, such as the method disclosed in US 3111517; and enantiomerically separated as reported by the method of Zhong et al., J. Chromatogr. A 1115 (2006) 19-45.
[0057] The above compounds and their salts can also be purchased from other chemical suppliers, such as suppliers in the PubChem database maintained by the National Center for Biotechnology Information (NCBI), examples of which can be verified on the various https: / / pubchem.ncbi.nlm.nih.gov web pages provided herein.
[0058] In a preferred embodiment, the compound is selected from bifenthrin, viflapon, clocromante, apellis, famotazole or a pharmaceutically acceptable salt thereof.
[0059] In a preferred embodiment, the compound is Viflabond or a pharmaceutically acceptable salt thereof, preferably Viflabond. The preferred Viflabond salt is a sodium salt, which is commercially available, such as THE BioTek (Ref. bt-285834); it can also be prepared by a suitable preparation method, such as the method disclosed in US 4970215.
[0060] In a preferred embodiment, the compound is biphenylpyridine or a pharmaceutically acceptable salt thereof, preferably biphenylpyridine. Preferred biphenylpyridine salts are acid addition salts, such as its hydrochloride, sulfate, succinate or maleate, which salts have been described in US Pat. No. 3,868,380.
[0061] In a particular embodiment, the compound is amopiquine or a pharmaceutically acceptable salt thereof, preferably amopiquine. A preferred amopiquine salt is a hydrochloride, more preferably a dihydrochloride, which is commercially available, such as Smolecule (Ref. S518740); a suitable preparation method may also be used, such as the method disclosed in Nobles et al., Journal of Pharmaceutical Sciences, Volume 52, Issue 6, June 1963, Pages 600-601.
[0062] In a preferred specific embodiment, the compound is clocromante or a pharmaceutically acceptable salt thereof, preferably a pharmaceutically acceptable salt thereof. The preferred clocromante salt is the hydrochloride, which is commercially available, such as Sigma-Aldrich (Ref. C4615); it can also be prepared using a suitable preparation method, such as the method disclosed in US 4452811 A.
[0063] In a preferred specific embodiment, the compound is apellisor a pharmaceutically acceptable salt thereof, preferably apellisor. A preferred apellisor salt is an acid addition salt, such as a hydrochloride, as described in US2010105711 A1, or commercially available from AdooQ Bioscience (Ref. A21794).
[0064] In a specific embodiment, the compound is benolate or a pharmaceutically acceptable salt thereof, preferably benolate. Benorate salts, such as its hydrochloride, are commercially available from, for example, AKOS Consulting & Solutions GmbH (Ref. AKOS015960742).
[0065] In a particular embodiment, the compound is xipamide or a pharmaceutically acceptable salt thereof, preferably xipamide. Preferred xipamide salts are ammonium salts and alkali metal salts, such as those disclosed in US Pat. No. 3,567,777.
[0066] In a preferred specific embodiment, the compound is famotazole or a pharmaceutically acceptable salt thereof, preferably a pharmaceutically acceptable salt thereof. A preferred famotazole salt is a hydrochloride (CAS 173352-39-1, 189638-30-0; https: / / pubchem.ncbi.nlm.nih.gov / compound / Afobazol). Another preferred salt is a dihydrochloride. These salts can be purchased from the market, such as Smolecule (Ref. S517427); they can also be prepared using a suitable preparation method, such as the method disclosed in US6376666B1.
[0067] In a particular embodiment, the compound is althiazide or a pharmaceutically acceptable salt thereof, preferably althiazide. Preferred althiazide salts are base addition salts, such as potassium salts, which are described in US Pat. No. 3,111,517.
[0068] The term "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not generally produce allergic or similar adverse reactions, such as stomach upset, dizziness, and the like, when administered to humans.
[0069] In addition, the term "pharmaceutically acceptable salt" refers to any salt that can (directly or indirectly) provide the compounds described herein after administration to a recipient. For example, the pharmaceutically acceptable salts of the compounds provided herein can be acid addition salts or base addition salts, and they can be synthesized from parent compounds by conventional chemical methods, and the parent compounds contain basic or acidic moieties. In general, these salts are prepared by, for example, reacting the free acid or base form of these compounds with a metered amount of a suitable base or acid in water or an organic solvent or in a mixture of the two. In general, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. Examples of acid addition salts include inorganic acid addition salts, such as, for example, hydrochlorides, hydrobromides, hydroiodides, sulfates, nitrates, phosphates, and organic acid addition salts, such as, for example, acetates, maleates, fumarates, citrates, oxalates, succinates, tartrates, malates, mandelates, methanesulfonates and p-toluenesulfonates. Examples of base addition salts include organic salts, such as, for example, ammonium salts, or inorganic salts, such as alkali metal salts, for example sodium or potassium salts.
[0070] The combination of the present invention is a combination of bifenthrin, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide with each other or with other compounds known to be useful for the treatment and / or prevention of dystrophinopathy. The present invention provides motivation for the production of the above combination for the first time.
[0071] In a preferred embodiment, the combination is a combination of two or more agents, the agent is selected from biphenylpyramide, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole, althiazide or a pharmaceutically acceptable salt thereof; etalerane, deflazacort, givinostat, triamterene, ifetroban, valmorolone, idebenone, prednisone, prednisolone, 20-hydroxyecdysone, metformin and L-citrulline combination, MA-0211, tamoxifen, dextrorotatory epicatechin, ex aluren, ARM-210, 2,6-disubstituted pyridazine-3(2H)-one, N-benzyl p-toluenesulfonamide, MP-101, MT-002, chlordiazepoxide, trexedrine hexaacetate, elagestrol, KER-050, SRP-5051, TXA-127, PB-1023, pembrolizumab, edelixin, grodixin, vitolaxin, casimsen, ATL-1102, NS-089, renadisen, WVEN-531, fordadistrogene movaparvovec, GNT-004, AAV1-follistatin viral vector, delandistrogenemoxeparvovec, AT-702, AAVrh74-GALGT2, SGT-001, CAP-2003, CAP-1002; wherein at least one of the agents is selected from bifenthrin, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide, or a pharmaceutically acceptable salt thereof.
[0072] Ataleron (CAS 775304-57-9; https: / / pubchem.ncbi.nlm.nih.gov / compound / 11219835) is a compound of the following formula:
[0073]
[0074] The compound enables ribosomes to read through mRNA containing premature stop codons and is commercialized under the brand name of Translarna for the treatment of DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-14832); it can also be synthesized using a suitable preparation method, such as the method disclosed in US20040204461.
[0075] Deflazacort (CAS 14484-47-0; https: / / pubchem.ncbi.nlm.nih.gov / compound / 189821) is a compound of the following formula:
[0076]
[0077] The compound is a glucocorticoid, with a trade name of Emflaza, used to treat DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-13609); or it can be synthesized by a suitable preparation method, such as the method disclosed in WO9721722.
[0078] Givinostat (CAS 497833-27-9; https: / / pubchem.ncbi.nlm.nih.gov / compound / 9804992) is a compound of the formula:
[0079]
[0080] The compound is a histone deacetylase inhibitor currently being developed for the treatment of DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-14842); it can also be synthesized using a suitable preparation method, such as the method disclosed in WO2020178776.
[0081] Triamterene, also known as TAS-205 (CAS 1244967-98-3; https: / / pubchem.ncbi.nlm.nih.gov / compound / 46911296) is a compound of the formula:
[0082]
[0083] The compound is a selective prostaglandin D2 synthase inhibitor, currently being developed for the treatment of DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-109134); it can also be synthesized using a suitable preparation method, such as the method disclosed in US8865714.
[0084] Ifetroban (CAS 143443-90-7; https: / / pubchem.ncbi.nlm.nih.gov / compound / 3037233) is a compound of the following formula:
[0085]
[0086] The compound is a thromboxane A2 / prostaglandin endoperoxide (TP) receptor antagonist and is currently being developed for the treatment of DMD. The compound can be purchased from the market, such as BOC Sciences (Ref. 143443-90-7); it can also be synthesized using a suitable preparation method, such as the method disclosed in US5332840.
[0087] Vamosone, also known as VBP-15 (CAS 13209-41-1; https: / / pubchem.ncbi.nlm.nih.gov / compound / 3035000) is a compound of the formula:
[0088]
[0089] The compound is a glucocorticoid analogue and is currently being developed for the treatment of DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-109017); it can also be synthesized using a suitable preparation method, such as the method disclosed in US9198921.
[0090] Idebenone (CAS 58186-27-9; https: / / pubchem.ncbi.nlm.nih.gov / compound / 3686) is a compound of the formula:
[0091]
[0092] The compound is a coenzyme Q10 analog and antioxidant analog, and is currently undergoing clinical trials for the treatment of DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-N0303); it can also be synthesized using a suitable preparation method, such as the method disclosed in EP21841.
[0093] Prednisone (CAS 53-03-2; https: / / pubchem.ncbi.nlm.nih.gov / compound / 5865) is a compound of the formula:
[0094]
[0095] The compound is a glucocorticoid analogue used for treating DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-B0214); or it can be synthesized by a suitable preparation method, such as the method disclosed in GB1063821.
[0096] Prednisolone (CAS 50-24-8; https: / / pubchem.ncbi.nlm.nih.gov / compound / 5755) is a compound of the formula:
[0097]
[0098] The compound is a glucocorticoid analogue used for treating DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-17463); or it can be synthesized by a suitable preparation method, such as the method disclosed in EP127294.
[0099] 20-Hydroxyecdysone, also known as BIO-101 or crustecdysone (CAS 5289-74-7; https: / / pubchem.ncbi.nlm.nih.gov / compound / 5459840), is a compound of the formula:
[0100]
[0101] The compound is a ecdysone, which is currently in the clinical development stage for the treatment of DMD. The product can be purchased from the market, such as MedChemExpress (Ref.HY-N6979), or can be synthesized using a suitable preparation method, such as the method disclosed in WO2012053994.
[0102] Metformin + L-citrulline is a combination of the two. Metformin (CAS 657-24-9; https: / / pubchem.ncbi.nlm.nih.gov / compound / 4091) is a compound of the following formula:
[0103]
[0104] L-citrulline (CAS 372-75-8; https: / / pubchem.ncbi.nlm.nih.gov / compound / 9750) is a compound of the following formula:
[0105]
[0106] The combination of metformin + L-citrulline has entered the clinical trial stage for the treatment of DMD. Metformin can be purchased from the market, such as MedChemExpress (Ref.HY-B0627), or it can be synthesized using a suitable preparation method, such as the method disclosed in WO2016059507. L-citrulline can be purchased from the market, such as MedChemExpress (Ref.HY-N0391), or it can be synthesized using a suitable preparation method, such as the method disclosed in GB1176266.
[0107] MA-0211 (also known as ASP-0367; MTB-1; bocidelpar sulfate) is a compound of the formula:
[0108]
[0109] The compound is a small molecule used as a PPAR-delta modulator. Mitobridge is conducting clinical development of the product for the treatment of DMD and mitochondrial diseases. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2017062468A1.
[0110] Tamoxifen (CAS 10540-29-1; https: / / pubchem.ncbi.nlm.nih.gov / compound / 2733526) is a compound of the following formula:
[0111]
[0112] The compound is a non-steroidal selective estrogen receptor modulator, which is currently in the clinical development stage for the treatment of DMD. The product can be purchased from the market, such as MedChemExpress (Ref.HY-13757A), or can be synthesized using a suitable preparation method, such as the method disclosed in US4536516.
[0113] Dextrorotatory epicatechin, also known as (+)-epicatechin (CAS 35323-91-2; https: / / pubchem.ncbi.nlm.nih.gov / compound / 182232), is a compound of the formula:
[0114]
[0115] This compound is a polyphenol extracted from green tea and is currently in the clinical development stage for the treatment of DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-N0001A), or synthesized using a suitable preparation method, such as the method disclosed in WO2014115174.
[0116] Exaluren (CAS 1375073-93-0; https: / / pubchem.ncbi.nlm.nih.gov / compound / 71461382) is a compound of the following formula:
[0117]
[0118] The compound is an aminoglycoside compound, which is currently being developed as a disulfate salt for the treatment of DMD and other diseases. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-114231), or can be synthesized using a suitable preparation method, such as the method disclosed in US8895519.
[0119] ARM-210 (CAS1467605-57-7; https: / / pubchem.ncbi.nlm.nih.gov / compound / 71761628) is a compound of the following formula:
[0120]
[0121] The compound is a ranolidine receptor / calcium release channel stabilizer and is currently in the clinical development stage for the treatment of DMD. The compound can be purchased from the market, such as Chemieliva (Ref. CB1384540), or can be synthesized using a suitable preparation method, such as the method disclosed in US8853198.
[0122] 2,6-disubstituted pyridazine-3 (2H) -ones suitable for treating DMD have been described in the art and are in clinical development for the treatment of DMD. Examples of suitable 2,6-disubstituted pyridazine-3 (2H) -ones are those described in WO2021231630. A particularly suitable example is compound 5 in WO2021231630.
[0123] N-Benzyl-p-toluenesulfonamide, also known as BTS (CAS 1576-37-0; https: / / pubchem.ncbi.nlm.nih.gov / compound / N-Benzyl-p-toluenesulfonamide), is a compound of the following formula:
[0124]
[0125] This compound is an inhibitor of fast fiber skeletal muscle myosin and has been shown to protect muscle from pathological muscle disorders in DMD animal models. This compound is commercially available, for example, from Sigma-Aldrich (Ref. 203895).
[0126] MP-101 (also known as 2,4-dinitrophenol) (CAS 51-28-5; https: / / pubchem.ncbi.nlm.nih.gov / compound / 1493) is a compound of the following formula:
[0127]
[0128] The compound is used as a mitochondrial regulator and is currently in the clinical development stage for the treatment of DMD. The compound is commercially available, such as Sigma-Aldrich (Ref. 07-5190), or can be synthesized using a suitable preparation method, such as the method disclosed in Khabarov et al., Russian Journal of Applied Chemistry, 2012, Vol. 85, No. 10, pp. 1577-1580.
[0129] MT-002, also known as AZD-9056 or MP-118, (CAS 345304-65-6; https: / / pubchem.ncbi.nlm.nih.gov / compound / 1493), is a compound of the formula:
[0130]
[0131] It is a P2X7 channel antagonist, currently in the clinical development stage for the treatment of DMD. The compound can be purchased from the market, such as Smolecule (Ref. S520142), or can be synthesized using a suitable preparation method, such as the method disclosed in US7297818.
[0132] Chlordiazepoxide (CAS 187870-78-6; https: / / pubchem.ncbi.nlm.nih.gov / compound / 9799487), also known as EMD-87580, is a compound of the following formula:
[0133]
[0134] It is Na + H +An inhibitor of the NHE-1 channel. The product is in the clinical development stage for the treatment of DMD. The compound can be purchased from the market, such as MedChemExpress (Ref.HY-19273), or can be synthesized using a suitable preparation method, such as the method disclosed in US5744641.
[0135] Tetracosactide hexaacetate (CAS22633-88-1; https: / / pubchem.ncbi.nlm.nih.gov / compound / Tetracosactide-hexaacetate), also known as Cosyntropin Depot, Synacthen Depot or MNK-1411, is a synthetic 24-amino acid melanocortin receptor agonist and adrenocorticotropic hormone (ACTH) analog. Mallinckrodt is developing the product clinically for the treatment of DMD. The product can be obtained by any suitable preparation method, such as the method disclosed in US2015110885.
[0136] Elapresterone (CAS 736992-21-5; https: / / pubchem.ncbi.nlm.nih.gov / compound / 11764719) is a synthetic peptide targeting cardiolipin, which is currently in clinical development for the treatment of DMD and other diseases. The product can be purchased from the market, such as Carbosynth (Ref.LEB99221), or can be obtained by any suitable preparation method, such as the method disclosed in US9988422.
[0137] KER-050 is a fusion protein that acts as a TGF beta inhibitor, and Keros Therapeutics is developing it clinically for the treatment of DMD. The product can be obtained by a suitable preparation method, such as the method disclosed in WO2018089706. In fact, any polypeptide defined in claim 1 of WO2018089706 (which is incorporated herein by reference) can be used as a medicament for the combination of the present invention.
[0138] SRP-5051 is a polypeptide phosphorodiamidate oligomer compound comprising eteplirsen conjugated to a cell penetrating peptide as an exon skipping therapy for exon 51 of myotrophin. The product is in clinical development for the treatment of DMD. The product can be obtained by a suitable preparation method, such as the method disclosed in WO2019079386. In fact, any peptide-oligonucleotide conjugate defined in claim 1 of WO2019079386 (which is incorporated herein by reference) can be used as a medicament for the combination of the present invention.
[0139] TXA-127 is angiotensin II 1-7 (CAS 39386-80-6; https: / / pubchem.ncbi.nlm.nih.gov / compound / 123805). This product is a naturally occurring small peptide that is currently in clinical development for the treatment of DMD. This product can be purchased from MedChemExpress (Ref HY-12403).
[0140] PB-1023, also known as Glymera (CAS1417579-81-7), is a long-acting glucagon-like peptide-1 (GLP-1) elastin-like peptide (ELP)-120 fusion protein that works by targeting the glucagon-like peptide 1 receptor (GLP1R). The product is in the clinical development stage for the treatment of DMD. The product can be obtained by a suitable preparation method, such as the method disclosed in WO2014113434A1.
[0141] Pembrolizumab, also known as FG-3019 (CAS 946415-13-0), is a recombinant human IgG1 / kappa monoclonal antibody against connective tissue growth factor (CTGF; CCN2). The product is in clinical development for the treatment of DMD and other fibrotic diseases. The product is commercially available from companies such as Creative Biolabs (Ref. TAB-443CQ).
[0142] Exondys (CAS1173755-55-9) is an antisense 30-mer phosphodiamidate morpholino oligonucleotide that targets exon 51 of the dystrophin gene. The product is marketed under the trade name Exondys 51 and is used to treat DMD patients with mutations that predispose to skipping exon 51. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2017205879.
[0143] Grodysin (CAS1422959-91-8) is an antisense phosphorodiamidate morpholino oligomer-based RNA therapy that targets exon 53 of the dystrophin gene. The product is marketed under the trade name Vyondys 53 and is used to treat DMD patients with mutations that predispose to skipping exon 53. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2021025899.
[0144] Viltepso (CAS 2055732-84-6) is a morpholino-based antisense oligonucleotide designed to skip exon 53 of the dystrophin gene. The product is commercialized under the trade name Viltepso for the treatment of DMD patients with mutations that predispose to skipping exon 53. The compound is commercially available from MedChemExpress (Ref. HY-132586).
[0145] Amondys 45 (CAS1422958-19-7) is an antisense RNA therapy based on antisense phosphorodiamidate morpholino oligomers that targets exon 45 of the dystrophin gene. The product is marketed under the trade name Amondys 45 and is used to treat DMD patients with mutations that predispose to skipping exon 45. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2017205879.
[0146] ATL-1102, also known as TV-1102 or ISIS-107248 (CAS 350263-41-1), is a second-generation antisense oligonucleotide that inhibits CD49d (subunit of VLA-4) mRNA (ITGA4 gene). The product is in clinical development at Antisense Therapeutics for the treatment of DMD. The product is described in Limmroth et al., Neurology. 2014 Nov 11; 83(20): 1780-1788 and can be synthesized using a suitable preparation method, such as the method disclosed in US6258790.
[0147] NS-089, also known as NCNP-02, is an exon-skipping antisense oligonucleotide targeting exon 44 of the dystrophin gene. The product is in clinical development for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in EP3660154. In fact, any antisense oligomer defined in claim 1 of EP3660154 A1 (which is incorporated herein by reference) can be used as an agent in the combination of the present invention.
[0148] Renardison, also known as DS-5141 (CAS1782108-31-9), is an oligonucleotide therapy that induces exon 45 skipping. The product is in clinical development for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in Ito et al. 2021 Current issues in molecular biology; 43(3): 1267-1281 (DOI: 10.3390 / cimb43030090).
[0149] WVEN-531 is a thiophosphate-modified nucleic acid that induces the skipping of exon 53 of the dystrophin gene. The product is in clinical development for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2019217784. In fact, any oligonucleotide defined in claims 1 to 5 of WO2019217784 (which is incorporated herein by reference) can be used as an agent in the combination of the present invention.
[0150] Fordadistrogene movaparvovec, also known as PF-06939926 or BMB-D001 (CAS2248111-37-5), is a gene therapy drug that uses a recombinant adeno-associated virus vector serotype 9 (AAV9) to deliver a functional dystrophin gene. Pfizer is developing this product clinically for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in CA2971303.
[0151] GNT-004 is an adeno-associated virus vector 8 (AAV8) gene therapy agent that encodes the micro-dystrophin gene. Genethon is clinically developing this product for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2015197232. Any composition defined in claim 1 of WO2015197232 (which is incorporated herein by reference) can be used as an agent in the combination of the present invention.
[0152] The AAV1-follistatin viral vector is an adeno-associated viral gene therapy agent that provides a muscle-specific transgenic follistatin, a sarcomeric protein and TGF beta ligand inhibitor. Milo Biotechnology is conducting clinical development of this product for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2008067480. Any composition defined in claim 1 of WO2008067480 (which is incorporated herein by reference) can be used as an agent in the combination of the present invention.
[0153] Delandistrogene moxeparvovec, also known as SRP-9001 or RG-6356 (CAS2305040-16-6), is a gene therapy drug that uses an adeno-associated virus serotype rh74 containing the human microdystrophin gene. Sarepta Therapeutics is clinically developing this product for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2021108755. Any carrier described in the invention of WO2021108755 (which is incorporated herein by reference) can be used as an agent in the combination of the present invention.
[0154] AT-702 is a recombinant adeno-associated virus 9 vector containing 4 antisense sequences that induce exon 2 skipping in the human DMD gene. Astellas is conducting clinical development of this product for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2014172669. Any recombinant adeno-associated virus defined in claim 1 of WO2014172669 (which is incorporated herein by reference) can be used as an agent in the combination of the present invention.
[0155] AAVrh74-GALGT2 is a gene therapy drug that uses a recombinant adeno-associated virus serotype rhesus 74 (rh74) to express the human CT GalNac transferase (GALGT2) gene. Sarepta Therapeutics is developing this product clinically for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2017049031. Any recombinant adeno-associated virus defined in claim 1 of WO2017049031 (which is incorporated herein by reference) can be used as an agent in the combination of the present invention.
[0156] SGT-001 is a micro-dystrophin gene therapy agent based on an adeno-associated virus serotype 9 vector, currently being developed for the treatment of DMD. The product is described in Bostick et al. 2008 Human Gene Therapy 19:851-856 (DOI: 10.1089 / hum.2008.058) and can be synthesized according to the disclosure.
[0157] CAP-2003 refers to extracellular vesicles, including exosomes, which are derived from cardiosphere-derived cells (CDC-EVs). These vesicles can deliver microRNAs and have properties that protect the heart and muscle regeneration. The product is in clinical development for the treatment of DMD. The product is described in WO2018195210 (which is incorporated herein by reference) and can be synthesized as disclosed therein.
[0158] CAP-1002 is a stem cell therapy developed by Capricor Therapeutics Inc for the treatment of DMD. The product can be synthesized using a suitable preparation method, such as the method disclosed in WO2013184527. Any cardiosphere-derived cell defined in claim 1 of WO201318452 (which is incorporated herein by reference) can be used as an agent in the combination of the present invention.
[0159] In a preferred specific embodiment, at least one of the agents included in the combination is viflapon or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0160] In a preferred specific embodiment, at least one of the pharmaceutical agents included in the combination is biphenylpyridine or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0161] In a specific embodiment, at least one of the pharmaceutical agents included in the combination is amopiquine or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0162] In a preferred specific embodiment, at least one of the pharmaceutical agents included in the combination is clocromante or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0163] In a preferred specific embodiment, at least one of the pharmaceutical agents included in the combination is apellisor or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0164] In a specific embodiment, at least one of the pharmaceutical agents included in the combination is benolate or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0165] In a specific embodiment, at least one of the pharmaceutical agents included in the combination is xipamide or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0166] In a preferred specific embodiment, at least one of the pharmaceutical agents included in the combination is famotazole or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0167] In a specific embodiment, at least one of the pharmaceutical agents included in the combination is althiazine or a pharmaceutically acceptable salt thereof, as described in any of the above embodiments.
[0168] In an embodiment, another of the two or more agents included in the combination is a compound such as etanerlan, deflazacort, givinostat, triamterene, ifetroban, valmorolone, idebenone, prednisone, prednisolone, 20-hydroxyecdysone, a combination of metformin and L-citrulline, MA-0211, tamoxifen, dex-epicatechin, exaluren, ARM-210, 2,6-disubstituted pyridazine-3(2H)-ones, N-benzyl-p-toluenesulfonamide, MP-101, MT-002, or chlordiazepoxide.
[0169] In another embodiment, another of the two or more agents included in the combination is a biological agent including a peptide or protein, such as troconazole hexaacetate, elagestrol, KER-050, SRP-5051, TXA-127 or PB-1023, wherein the protein can particularly be an antibody, such as pembrolizumab; a nucleic acid, such as edrenolide, gorodizan, vitolasen, casimsen, ATL-1102, NS-089, renaldisan or WVEN-531, wherein the nucleic acid can be administered by using a viral vector, such as fordadistrogene movaparvovec, GNT-004, AAV1-follicle-stimulating agent viral vector, delandistrogenemoxeparvovec, AT-702, AAVrh74-GALGT2 or SGT-001; or can be administered by using cells and materials obtained therefrom, such as CAP-2003 or CAP-1002.
[0170] The present invention relates to the medical use of the compounds and combinations for the treatment and / or prevention of dystrophinopathy. The term "dystrophinopathy" as used in the present invention refers to any disease or disorder caused by a lack or deficiency of dystrophin. Non-limiting examples of diseases or disorders caused by a lack or deficiency of dystrophin are DMD, BMD, DMD-related dilated cardiomyopathy or cramps associated with myoglobinuria. Preferably, the disease or disorder caused by a lack or deficiency of dystrophin is selected from DMD and BMD, and even more preferably DMD.
[0171] As used herein, the terms "treat" and "treatment" mean reversing, alleviating, inhibiting the progression of a disease or disorder, or the progression of one or more symptoms of the disease or disorder, such as muscle weakness, heart enlargement, respiratory distress, scoliosis, joint contractures, calf muscle hypertrophy, or cognitive impairment, relative to pre-treatment levels.
[0172] As used herein, the terms "preventing" and "prevention" refer to avoiding or inhibiting the occurrence of the disease or disorder or one or more of the symptoms.
[0173] The compound used according to the present invention can be used by any appropriate route. The non-limiting examples of route of administration include oral, parenteral (such as subcutaneous, intramuscular, intravenous, etc.), topical, sublingual, inhalation, rectal, vaginal or ocular routes. In a preferred embodiment, the compound used according to the present invention is used by oral or parenteral routes, and vein and muscle routes are particularly preferred parenteral routes.
[0174] In particular, the compounds used according to the present invention are administered in the form of a pharmaceutical composition, which includes the corresponding active compound and one or more pharmaceutically acceptable excipients. The term "pharmaceutically acceptable excipient" refers to a carrier, diluent or adjuvant administered together with the active ingredient. The composition of the pharmaceutically acceptable excipient necessarily depends on the selected route of administration, etc. The pharmaceutical composition can be manufactured according to conventional methods known to those of ordinary skill in the art, such as the methods described in the Spanish Pharmacopoeia and the United States Pharmacopoeia.
[0175] Therefore, the present invention also relates to a pharmaceutical composition comprising a compound selected from biphenylamine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide or a pharmaceutically acceptable salt thereof, or a combination according to the present invention; and at least one pharmaceutically acceptable excipient; for the treatment or prevention of dystrophinopathy.
[0176] Similarly, the present invention also relates to the use of a pharmaceutical composition in the manufacture of a medicament for treating and / or preventing dystrophinopathy, the pharmaceutical composition comprising a compound selected from biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide or a pharmaceutically acceptable salt thereof, or a combination according to the present invention; and at least one pharmaceutically acceptable excipient.
[0177] Similarly, the present invention also relates to a method for treating and / or preventing dystrophinopathy in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound selected from biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazine or a pharmaceutically acceptable salt thereof, or a combination according to the present invention; and at least one pharmaceutically acceptable excipient.
[0178] In yet an additional aspect, the present invention also relates to a pharmaceutical composition comprising the combination of the present invention; and at least one pharmaceutically acceptable excipient.
[0179] In one embodiment, the pharmaceutical composition is in the form of oral administration. Suitable oral dosage forms may be tablets and capsules, and may contain conventional excipients known in the art, such as binders, such as syrup, gum arabic, gelatin, sorbitol, tragacanth or polyvinyl pyrrolidone; fillers, such as lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; lubricants for preparing tablets, such as magnesium stearate; disintegrants, such as starch, polyvinyl pyrrolidone, sodium starch glycolate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents, such as sodium lauryl sulfate. Solid oral compositions may be prepared by conventional methods, such as mixing, filling or compression. Alternatively, suitable oral dosage forms may be in the form of solutions or suspensions, in particular, powders or granules comprising the compounds or combinations of the present invention are dissolved or dispersed in a liquid medium. When administering medication to pediatric patients, oral solutions or suspensions are particularly preferred.
[0180] In one embodiment, the pharmaceutical composition is administered parenterally, preferably by intravenous or intramuscular injection.
[0181] The pharmaceutical form suitable for parenteral administration can be a sterile solution or suspension based on an aqueous carrier such as water or sodium chloride, Ringer's solution or glucose solution; a water-miscible carrier, including but not limited to ethanol, polyethylene glycol and polypropylene glycol; or a non-aqueous carrier, including but not limited to corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate and benzyl benzoate. Suitable excipients such as fillers, buffers or surfactants can be used.
[0182] The compounds used according to the present invention are preferably administered in or included in a pharmaceutical composition or combination in a "therapeutically effective amount", i.e., a non-toxic but sufficient amount of the corresponding compound to achieve the desired effect, i.e., treatment and / or prevention of dystrophinopathy. An "effective" amount varies from person to person, depending on the age and general condition of the individual, the specific compound administered, etc. Therefore, it is not always possible to specify an exact "therapeutically effective amount". However, one of ordinary skill in the art can determine the appropriate amount in any individual case using routine knowledge and experimentation.
[0183] The term "subject" preferably refers to a mammal, such as a human. In a preferred embodiment, in any embodiment described herein, the subject for treating or preventing dystrophinopathy is a pediatric subject. A pediatric subject refers to a person 21 years of age or younger, such as a newborn (from birth to the first 28 days after birth), an infant (29 days to less than 2 years of age), a child (2 years to less than 12 years of age), a teenager (12 years to 21 years of age, until but not including the 22nd birthday).
[0184] The compounds used according to the invention are typically administered once or more per day, for example 1, 2, 3 or 4 times per day, and the typical total daily dose depends on a variety of factors, such as the specific compound to be administered, the severity of the disease or the weight or age of the patient (many dystrophinopathy patients are pediatric patients), all of which are well known to skilled physicians who can determine the appropriate dose based on their general knowledge.
[0185] Typical total daily dosages of Viflabond or its pharmaceutically acceptable salts range from 1 to 3000 mg / day (expressed as Viflabond free base), preferably from 30 to 1500 mg / day. The compound can be administered by oral route.
[0186] Typical total daily doses of biphenylpyridine or a pharmaceutically acceptable salt thereof range from 1 to 3000 mg / day (expressed as biphenylpyridine free base), preferably from 10 to 1500 mg / day. The compound may be administered by oral route.
[0187] The typical total daily dose of amopiquine or a pharmaceutically acceptable salt thereof ranges from 0.1 to 250 mg / kg / day (expressed as amopiquine free base), preferably from 1 to 25 mg / kg / day. The compound may be administered parenterally, preferably intramuscularly.
[0188] The typical total daily oral dose of clocromante or its pharmaceutically acceptable salt is 1 to 1000 mg / day (expressed as clocromante free base), preferably 10 to 300 mg / day. The typical total intravenous dose of clocromante or its pharmaceutically acceptable salt is 1 to 100 mg / day (expressed as clocromante free base), preferably 10 to 30 mg / day.
[0189] Typical total daily doses of apellisor or a pharmaceutically acceptable salt thereof range from 1 to 2000 mg / day (expressed as apellisor free base), preferably from 10 to 500 mg / day. The compound may be administered by the oral route.
[0190] Typical total daily doses of benolate or a pharmaceutically acceptable salt thereof range from 0.05 to 50 g / day (expressed as benolate free base), preferably from 0.5 to 20 g / day. The compound may be administered by the oral route.
[0191] Typical total daily doses of xipamide or a pharmaceutically acceptable salt thereof range from 1 to 200 mg / day (expressed as xipamide free base), preferably from 10 to 80 mg / day. The compound may be administered by the oral route.
[0192] Typical total daily doses of famotazole or a pharmaceutically acceptable salt thereof range from 1 to 100 mg / day (expressed as famotazole free base), preferably from 10 to 60 mg / day. The compound may be administered by the oral route.
[0193] The typical total daily dose of althiazine or a pharmaceutically acceptable salt thereof ranges from 1 to 1000 mg / day (expressed as althiazine free base), preferably from 10 to 100 mg / day. The compound can be administered by oral route.
[0194] The compounds used according to the present invention can be administered as the sole active ingredient; they can also be used in combination with other active ingredients as described elsewhere herein. In a specific embodiment, the compound is used as the sole active ingredient. In another specific embodiment, the compound is used in combination with other active ingredients as described elsewhere herein.
[0195] The term "combination" refers to a product comprising one or more of the compounds mentioned, which may be a single composition or several compositions (or units), in which case the corresponding compounds are distributed among the several compositions.
[0196] When the combination is in the form of a single composition, the compounds of the combination are always administered simultaneously.
[0197] When the combination is in the form of several compositions (or units), each composition contains at least one but not all of the compounds of the combination, and these compositions or (units) may be administered simultaneously, sequentially or separately.
[0198] Simultaneous administration refers to the administration of compounds or compositions (or units) at the same time.
[0199] Sequential administration refers to the administration of the compounds or compositions (or units) at different time points in a staggered manner.
[0200] Separate administration means that the compounds or compositions (or units) are administered independently of each other at different time points.
[0201] The following examples represent specific embodiments of the present invention. They are not intended in any way to limit the scope of the invention defined in this description.
[0202] Example
[0203] Example 1 mdx 5cv Utrophin upregulation in myotubes
[0204] Materials and methods
[0205] Preparation of MDX myotubes
[0206] From mdx 5cv Myotube cultures were prepared in mice, a DMD mouse model generated by chemical mutagenesis that does not express dystrophin and has a more severe phenotype than the classical mdx mouse model (Jackson Laboratory; Beastrom et al. Am J Pathol 2011, 179: 2464-2474; DOI: 10.1016 / j.ajpath.2011.07.009). As previously described, satellite cell-derived primary myoblasts were isolated by cell surface antibodies and magnetic separation and cultured to expand (Motohashi et al., J Vis Exp. 2014 Apr 8; (86): 50846). Briefly, after collagenase (Worthington, CLS-2) treatment, myotube cultures were obtained from mdx mice. 5cv Cells isolated from mouse hind limb muscle were incubated with anti-CD31 monoclonal antibody conjugated to phycoerythrin (eBioscience, 12-0311), anti-CD45 monoclonal antibody conjugated to phycoerythrin (eBioscience, 30-F11), anti-Sca1 monoclonal antibody conjugated to phycoerythrin (eBioscience, 12-81) and anti-integrin α7 (MBL International, ABIN487462), followed by incubation with anti-PE microbeads (Miltenyi Biotec, 130-048-801) and then separated by LD column (Miltenyi Biotec, 130-042-901). The negative cell population was incubated with anti-mouse IgG beads (Miltenyi Biotec, 130-048-402) and then separated by MS column (Miltenyi Biotec, 130-042-201) to isolate integrin α7 (+) satellite cells. Satellite cell-derived mdx 5cvMyoblasts were maintained in myoblast culture medium containing 20% FBS and 20 ng / mL bFGF (Invitrogen, PHG0263) in HAM's-F10 medium on collagen-coated plates. Cell cultures were kept in a humidified incubator at 37°C with 5% CO2 and 5% O2. mdx was induced under low serum conditions (DMEM supplemented with 5% horse serum). 5cv Myoblasts differentiate into multinucleated myotubes.
[0207] Test compound
[0208] Halofuginone was obtained from Selleck. Viflapon and clocroman hydrochloride were obtained from Sigma. Famotazole hydrochloride was obtained from MedChemExpress. Diphenylpyridine was obtained from Enamine. Amopiquine and apellis were obtained from Carbosynth. Benormate and xipamide were obtained from Fluorochem. Althiazide was obtained from Toronto Research Chemicals. All compounds were dissolved in 100% DMSO to a 10 mM stock solution.
[0209] Processing of myotubes
[0210] Compounds at different concentrations (0.01-10 μM) were added to the mdx cells daily by replacing the differentiation medium. 5cvmyotubes. After 3 days of compound exposure, cells were collected and RNA was extracted using TRIzol reagent (15596026, ThermoFisher Scientific). The isolated RNA was subjected to cDNA synthesis using random primers using the Transcriptor First Strand cDNA Synthesis Kit (04379012001, Roche Molecular Diagnostics). Diluted DMSO solution was used as a negative control. qRT-PCR assay of utrophin-A expression was performed using the following primers: Utro-F1 (forward) 5'-CCTGATGATGGGCAGAACGAATTC-3' (SEQ ID NO: 1) and Utro-R1 (reverse) 5'-CTGATGGGTGGTTTCCCACTCTTG-3' (SEQ ID NO: 2). 18S rRNA was used as an internal control, and the primers were as follows: 18S-F1 (forward) 5'-CGCACGGCCGGTACAGTGAAACTG-3' (SEQ ID NO: 3) and 18S-R1 (reverse) 5'-CACCCGTGGTCACCATGGTAGGCA-3' (SEQ ID NO: 4). qPCR was performed using GoTaq qPCR Master Mix (A6001, Promega). All primers were synthesized as custom DNA oligonucleotides by Integrated DNA technologies (IDT). The ΔCt method was used for analysis. Statistical analysis was performed using at least 3 independent experiments with 2-4 replicates per experiment.
[0211] result
[0212] At different concentrations, in mdx 5cv Chemical compounds were tested in myotubes for 3 days. Halofuginone was used as a positive control for utrophin upregulation. These molecules repeatedly showed significant upregulation of utrophin expression (from 5% to 44% depending on the compound and its concentration range). Table 1 shows the mdx expression by RT-PCR 5cv Utrophin upregulation values in myotubes (values correspond to fold changes in utrophin compared to DMSO expressed as mean ± sem values).
[0213] Table 1
[0214] Table 1: mdx treated with different compounds at 0.1μM, 1μM and 10μM 5cv Utrophin upregulation in myotubes (mean ± sem fold change of utrophin compared to DMSO).
[0215] deal with 0.1μM 1μM 10μM Halofuginone (control) 1.44±0.37 1.24±0.10 1.30±0.04 Viv Lapon 1.43±0.24 1.35±0.02 1.05±0.15 Biphenylpyridine 1.24±0.13 1.10±0.21 1.23±0.21 Amopiquine 1.23±0.11 1.10±0.14 1.23±0.37 Chloroform Hydrochloride 1.06±0.19 1.07±0.22 1.34±0.13 Apelles 1.08±0.09 1.45±0.11 1.40±0.13 Benoate 1.16±0.12 1.04±0.16 1.58±0.29 Xipamide 1.25±0.18 1.05±0.17 1.18±0.10 Famotazole hydrochloride 1.34±0.07 1.04±0.10 1.34±0.19 Althiazide 1.09±0.07 1.33±0.09 1.33±0.09
[0216] Human 3D Skeletal Muscle Culture Research
[0217] Materials and methods
[0218] Preparation and processing of human 3D skeletal muscle tissue
[0219] Human 3D skeletal muscle tissue was fabricated using a polydimethylsiloxane (PDMS; Sylgard 184 silicon elastomer kit, Dow Corning) mold developed and manufactured as described in Fernández-Costa et al. 2022. In brief, the design of the mold consists of a square pool, which is the inoculation pool for the cell / hydrogel solution, and two vertical flexible PDMS columns. The PDMS mold for muscle cell culture was prepared as follows: first, it was ultrasonically cleaned in water containing soap, 2-propanol, and Mili-Q water, and sterilized under UV light for 15 min. It was then sterilized using 1% in cold PBS (100 μl / well) at 4°C. F-127 (Sigma-Aldrich) solution was used for treatment for 1 h.
[0220] Human 3D skeletal muscle tissue was generated using immortalized human muscle satellite cells (iHuMSCs) from a DMD patient (DMD 2, clone G82) (Massenet et al. 2020). iHuMSCs were cultured in growth medium (Skeletal Muscle Basal Medium (PromoCell GmbH), Skeletal Muscle Supplement Mix (PromoCell GmbH), 10% fetal bovine serum (FBS) (Gibco TM ), 100 U / mL penicillin and 100 μg / mL streptomycin (Gibco TM iHuMSCs were released from the culture flask using a small amount of trypsin. The cells were plated at 2.5×10 7 cells / ml encapsulated in 30% v / v Growth Factor Reduced (GFR) Basement Membrane Matrix 2 units of thrombin from human plasma (Sigma-Aldrich) and 4 mg / mL of fibrinogen from human plasma (50% v / v) (Sigma-Aldrich) were added to the cell / hydrogel mixture. 35 μl were pipetted using a cooled tip in each PDMS mold to avoid premature polymerization.
[0221] The cell / hydrogel mixture was polymerized for 30 min at 37°C and then incubated in growth medium containing 1 mg / mL 6-aminocaproic acid (ACA) (Sigma-Aldrich). ACA acts as an antifibrinolytic agent, which prevents fibrin depolymerization. The cells were maintained in growth medium for 2 days and then switched to differentiation medium (Dulbecco's Modified Eagle Medium, High Glucose, GlutaMAX TM Supplements (Gibco TM ), which contains 1% KnockOut TM Serum replacement (Gibco TM , 1% insulin-transferrin-selenium-ethanolamine (Gibco TM ) and 1% penicillin-streptomycin-glutamine (Gibco TM )) for 7 days. Half the volume of differentiation medium was replaced every 2 days. After 5 days of differentiation, the medium was replaced with differentiation medium containing drugs at a final concentration of 10 μM and 0.01% DMSO. The treatment lasted for 48 h.
[0222] Example 2 Increase in muscle contraction force in response to electrical stimulation
[0223] Electrical pulse stimulation (EPS) and video analysis
[0224] Human 3D skeletal muscle tissue was subjected to electrical stimulation after seven days of differentiation to induce muscle contraction. The custom-made device used to perform EPS consisted of a 12-well plate with two graphite electrodes per well, located on the plate cover. The PDMS mold was placed on a 12-well plate filled with fresh differentiation medium. The plate was placed on a Zeiss Axio Observer Z1 / 7 equipped with an XL S1 cell culture incubator at 37°C and 5% carbon dioxide. The device was connected to a pulse generator (Multifunction Generator WF1974, NF Corporation) and the tissue was stimulated with square wave electrical pulses of 1V / mm, 1ms pulse width and frequency from 1 to 50Hz. The contractility of the EPS response with a frequency of 1Hz was evaluated to study the kinetics of single contractions. On the other hand, a frequency of 50Hz was used to induce tetanic contractions.
[0225] Videos of cast strut movement in response to muscle contraction were captured using a ZEISS Axio Observer Z1 / 7 microscope. The cross-sectional area and tissue position along the strut axis were also recorded during the test. The videos were analyzed using a custom Python script, and the specific forces generated by the tissue were calculated by applying Euler's displacement theorem and the calculated strut displacements as described in Mestre et al. 2018. The ankylosing index was calculated as the ratio of the maximum ankylosing specific force divided by the maximum single specific force.
[0226] Bioengineered DMD patient-derived 3D skeletal muscle tissues were differentiated and treated with 10 μM of viflapon or biphenylpyridine for 2 days, and then the contractile force of the muscles under electrical stimulation was measured. Muscle tissues treated with 0.01% DMSO served as negative controls.
[0227] The results are as follows Figures 1 to 3 As shown below: Improved muscle function of three-dimensional skeletal muscle tissue derived from DMD patients: Immortalized three-dimensional skeletal muscle tissue derived from DMD patients was differentiated for 5 days and treated with 10 μM viflapon, 10 μM diphenylpyridine or 0.01% DMSO for 2 days. The muscles were electrically stimulated and the maximum single ( Figure 1 ) or ankylosing ( Figure 2 ) contractile force and compared it with the force obtained with DMSO-treated muscles. Graphs present the maximum contractile force normalized to tissue area as mean ± sem. The tonic index ( Figure 3 ) and are presented as mean ± sem. Statistical significance after Anova calculation and Dunnett test correction is represented by P value: **(P ≤ 0.01); ***(P ≤ 0.001); ****(P ≤ 0.0001).
[0228] like Figures 1 to 3 As shown, muscle function was improved after treatment with viflapon and diphenylpyridine, as demonstrated by an increase in muscle contraction force in response to electrical stimulation. Compared to cells treated with DMSO, single contraction force ( Figure 1 ) and tetanic force ( Figure 2 In addition, after treatment with these two compounds, the myotonic index ( Figure 3 ) increased significantly.
[0229] Example 3. Detection of utrophin expression using immunohistochemistry
[0230] Cryosectioning
[0231] Human 3D skeletal muscle tissue was fixed in 10% formalin solution (about 4% formaldehyde) (Sigma-Aldrich) at room temperature for 30 minutes, and then washed three times with PBS for 5 minutes each time. The sample was removed from the PDMS platform and placed in 30% sucrose solution (in PBS) for 48 hours with stirring at 4°C. Using a batch of isopentane frozen with liquid nitrogen, the sample was embedded in a disposable plastic The samples were frozen in optimal cutting temperature compound (OCT compound) (PolyFreeze, Sigma-Aldrich) in VWR. The samples were stored at -20°C before sectioning. The samples were sectioned using a cryostat (Leica CM1900) to obtain transverse sections with a thickness of 20 μm, which were placed on a SuperFrost Plus TM The samples were adhered to slides (Fisher Scientific) and stored at -20°C until staining.
[0232] Immunohistochemistry
[0233] Use PAP pen (ImmEdge TM , Vector laboratories) were surrounded with slides containing tissue sections and then dialyzed with PBS-T (0.1% Triton-X (Sigma-Aldrich) in PBS) for 10 min, followed by incubation with blocking buffer (0.3% Triton-X, 3% donkey serum (Sigma-Aldrich) in PBS) for 30 min at room temperature. Then, the samples were incubated with primary antibodies (monoclonal mouse anti-utrophin primary antibody (MANCHO7)) in blocking buffer at 4°C overnight. After washing with PBS-T three times (5 min each time), the samples were incubated with Alexa Fluor TM The cells were incubated with polyclonal donkey anti-mouse IgG secondary antibody conjugated to 488 for 45 min at room temperature. TM Tissue sections were mounted with mounting medium (Thermo Fisher). The edges of the coverslip were sealed with nail polish.
[0234] Imaging and image analysis
[0235] Fluorescence images were acquired by a ZEISS LSM800 confocal laser scanning microscope. Images were analyzed using the Fiji image processing package in Image J (Schindelin et al., 2012). For fluorescence quantification, the mean gray value of each image was measured (minimum 4 images per tissue).
[0236] Statistics
[0237] Results are presented as mean ± SEM. Statistical significance was determined by one-way ANOVA and Dunnett's multiple comparison test using GraphPad Prism. P values < 0.05 were considered statistically significant.
[0238] result
[0239] Bioengineered DMD patient-derived 3D skeletal muscle tissues were differentiated and treated with 10 μM viflapon or biphenylpyridine for 2 days before measuring utrophin expression. Muscle tissues treated with 0.01% DMSO served as negative controls.
[0240] The results are as follows Figure 4 As shown, as follows: Increased expression of utrophin in human DMD cultures: Immortalized DMD patient-derived 3D skeletal muscle tissue was differentiated for 5 days and treated with 10 μM viflapon, 10 μM diphenylpyridine, or 0.01% DMSO for 2 days. The expression of utrophin in muscle slices was detected by immunohistochemistry and compared with the signal observed in DMSO-treated cells. The graph represents the fold increase in fluorescence values compared with DMSO, expressed as mean ± sem. Statistical significance calculated by analysis of variance and corrected by Dunnett's test is indicated by P value: ** (P ≤ 0.01); **** (p ≤ 0.0001).
[0241] Compared with DMSO-treated cells, human DMD 3D muscle tissue treated with viflapon and diphenylpyridine showed a 3-fold increase in utrophin expression, confirming previous results in mdx myotubes (Table 1).
[0242] Overall, these results suggest that these compounds help increase utrophin expression and improve muscle function, indicating their potential for use in the treatment of dystrophinopathies.
Claims
1. A compound selected from the group consisting of biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of dystrophinopathy.
2. The compound for use according to claim 1, wherein the compound is selected from biphenylpyridine, viflapon, clocromante, apellis, famotazole or a pharmaceutically acceptable salt thereof.
3. The compound for use according to any one of claims 1 and 2, wherein the compound is biphenylpyridine or a pharmaceutically acceptable salt thereof.
4. The compound for use according to any one of claims 1 and 2, wherein the compound is viflapon or a pharmaceutically acceptable salt thereof.
5. The compound for use according to any one of claims 1 and 2, wherein the compound is clocromante or a pharmaceutically acceptable salt thereof.
6. The compound for use according to any one of claims 1 and 2, wherein the compound is apellisor or a pharmaceutically acceptable salt thereof.
7. The compound for use according to any one of claims 1 and 2, wherein the compound is famotazole or a pharmaceutically acceptable salt thereof.
8. A combination of two or more agents selected from the group consisting of biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide, or a pharmaceutically acceptable salt thereof; etalerane, deflazacort, givinostat, triamterene, ifetroban, vamorolone, idebenone, prednisone, prednisolone, 20-hydroxyecdysone, a combination of metformin and L-citrulline, MA-0211, tamoxifen, dextran, exalur en, ARM-210, 2,6-disubstituted pyridazine-3(2H)-one, N-benzyl p-toluenesulfonamide, MP-101, MT-002, chlordiazepoxide, trexedrine hexaacetate, elagestrol, KER-050, SRP-5051, TXA-127, PB-1023, pembrolizumab, edelison, grodisin, vitolason, casimson, ATL-1102, NS-089, renardison, WVEN-531, fordadistrogene movaparvovec, GNT-004, AAV1-follistatin viral vector, delandistrogenemoxeparvovec, AT-702, AAVrh74-GALGT2, SGT-001, CAP-2003, CAP-1002; wherein at least one of the agents is selected from vivrapone, bifenthrin, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide, or a pharmaceutically acceptable salt thereof, and is used in the treatment or prevention of dystrophinopathy.
9. The combination for use according to claim 8, wherein at least one of the agents is selected from biphenylpyridine, viflapon, clocromante, apellis, famotazole, or a pharmaceutically acceptable salt thereof.
10. The pharmaceutical composition comprises: - a compound selected from biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazine, or a pharmaceutically acceptable salt thereof; or a combination according to any one of claims 8 to 9; and - at least one pharmaceutically acceptable excipient, It is used in the treatment or prevention of dystrophinopathy.
11. The pharmaceutical composition for use according to claim 10, wherein the pharmaceutical composition is administered orally or parenterally.
12. A compound for use according to any one of claims 1 to 7, or a combination for use according to any one of claims 8 to 9, or a pharmaceutical composition for use according to any one of claims 10 to 11, wherein the dystrophinopathy is selected from Duchenne muscular dystrophy, Becker muscular dystrophy, Duchenne muscular dystrophy-associated dilated cardiomyopathy or cramps with myoglobinuria.
13. A compound for use according to any one of claims 1 to 7, or a combination for use according to any one of claims 8 to 9, or a pharmaceutical composition for use according to any one of claims 10 to 11, wherein the dystrophinopathy is Duchenne muscular dystrophy.
14. A compound for use according to any one of claims 1-7 and 12, 13; or a combination for use according to any one of claims 8, 9, 12 and 13; or a pharmaceutical composition for use according to any one of claims 10-13; wherein the treatment or prevention of the dystrophinopathy is in a pediatric subject.
15. Use of a compound selected from biphenylpyramide, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing dystrophinopathy.
16. The use according to claim 15, wherein the compound is selected from biphenylpyridine, viflapon, clocromante, apellis, famotazole or a pharmaceutically acceptable salt thereof.
17. The use according to any one of claims 15 and 16, wherein the compound is biphenylpyridine or a pharmaceutically acceptable salt thereof.
18. The use according to any one of claims 15 and 16, wherein the compound is viflapon or a pharmaceutically acceptable salt thereof.
19. The use according to any one of claims 15 and 16, wherein the compound is clocromante or a pharmaceutically acceptable salt thereof.
20. The use according to any one of claims 15 and 16, wherein the compound is apellisor or a pharmaceutically acceptable salt thereof.
21. The use according to any one of claims 15 and 16, wherein the compound is famotazole or a pharmaceutically acceptable salt thereof.
22. The use of a combination of two or more agents for the manufacture of a medicament for treating or preventing dystrophinopathy, wherein the agent is selected from biphenylpyramide, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole, althiazide or a pharmaceutically acceptable salt thereof; etalerane, deflazacort, givinostat, triamterene, ifetroban, vamorolone, idebenone, prednisone, prednisolone, 20-hydroxyecdysone, a combination of metformin and L-citrulline, MA-0211, tamoxifen, dextromethorphan, tamoxifen ... Epicatechin, exaluren, ARM-210, 2,6-disubstituted pyridazine-3(2H)-one, N-benzyl p-toluenesulfonamide, MP-101, MT-002, chlordiazepoxide, troconazole hexaacetate, elagestrol, KER-050, SRP-5051, TXA-127, PB-1023, pembrolizumab, edelison, grodisin, vitolason, casimson, ATL-1102, NS-089, renardison, WVEN-531, fordadistrogene movaparvovec, GNT-004, AAV1-follistatin viral vector, delandistrogene moxeparvovec, AT-702, AAVrh74-GALGT2, SGT-001, CAP-2003, CAP-1002; wherein at least one of the agents is selected from vivrapone, bifenthrin, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide, or a pharmaceutically acceptable salt thereof.
23. The use of a combination according to claim 22, wherein at least one of the agents is selected from biphenylpyridine, viflapon, clocromante, apellis, famotazole or a pharmaceutically acceptable salt thereof.
24. Use of a pharmaceutical composition for manufacturing a medicament for treating or preventing dystrophinopathy, the composition comprising: - a compound selected from biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazine, or a pharmaceutically acceptable salt thereof; or a combination as claimed in any one of claims 22 and 23; and - at least one pharmaceutically acceptable excipient.
25. Use of the pharmaceutical composition according to claim 24, wherein the pharmaceutical composition is administered orally or parenterally.
26. Use of a compound according to any one of claims 15-21, or use of a combination according to any one of claims 22 and 23, or use of a pharmaceutical composition according to any one of claims 24 and 25, wherein the dystrophinopathy is selected from Duchenne muscular dystrophy, Becker muscular dystrophy, Duchenne muscular dystrophy-associated dilated cardiomyopathy or cramps with myoglobinuria.
27. Use of a compound according to any one of claims 15-21, or use of a combination according to any one of claims 22 and 23, or use of a pharmaceutical composition according to any one of claims 24 and 25, wherein the dystrophinopathy is Duchenne muscular dystrophy.
28. Use of a compound according to any one of claims 15-21, 26 and 27; or use of a combination according to any one of claims 22, 23, 26 and 27; or use of a pharmaceutical composition according to any one of claims 24, 25, 26 and 27; wherein the treatment or prevention of the dystrophinopathy is in a pediatric subject.
29. A method for treating or preventing dystrophinopathy in a patient in need thereof, comprising administering to the patient a compound selected from the group consisting of biphenylpyramide, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazine, or a pharmaceutically acceptable salt thereof.
30. The method of claim 29, wherein the compound is selected from bifenthrin, viflapon, clocromante, apellis, famotazole, or a pharmaceutically acceptable salt thereof.
31. The method according to any one of claims 29 and 30, wherein the compound is selected from biphenylpyridine or a pharmaceutically acceptable salt thereof.
32. The method according to any one of claims 29 and 30, wherein the compound is selected from Viflapon or a pharmaceutically acceptable salt thereof.
33. The method according to any one of claims 29 and 30, wherein the compound is selected from clocromante or a pharmaceutically acceptable salt thereof.
34. The method according to any one of claims 29 and 30, wherein the compound is selected from apellisor or a pharmaceutically acceptable salt thereof.
35. The method according to any one of claims 29 and 30, wherein the compound is selected from famotazole or a pharmaceutically acceptable salt thereof.
36. A method for treating or preventing dystrophinopathy in a patient in need thereof, comprising administering to the patient a combination comprising two or more agents selected from the group consisting of biphenylpyramide, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole, althiazide or a pharmaceutically acceptable salt thereof; etalerane, deflazacort, givinostat, triamterene, ifetroban, vamotrolon, idebenone, prednisone, prednisolone, 20-hydroxyecdysone, a combination of metformin and L-citrulline, MA-0211, tamoxifen, dex-epicatechin, exaluren, ARM-210, 2,6-disubstituted pyridazine-3(2H)-one, N-benzyl p-toluenesulfonamide, MP-101, MT-002, chlordiazepoxide, trexedrine hexaacetate, elagestrol, KER-050, SRP-5051, TXA-127, PB-1023, pembrolizumab, edrenolide, grodisin, vitolasen, casimsen, ATL-1102, NS-089, renardisin, WVEN-531, fordadistrogene movaparvovec, GNT-004, AAV1-follistatin viral vector, delandistrogene moxeparvovec, AT-702, AAVrh74-GALGT2, SGT-001, CAP-2003, CAP-1002; wherein at least one of the agents is selected from vivrapone, bifenthrin, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazide, or a pharmaceutically acceptable salt thereof.
37. The method of claim 36, wherein at least one of the agents is selected from bifenthrin, viflapon, clocromante, apellis, famotazole, or a pharmaceutically acceptable salt thereof.
38. A method of treating or preventing dystrophinopathy in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising: - a compound selected from biphenylpyridine, viflapon, amopiquine, clocromante, apellis, benolate, xipamide, famotazole and althiazine, or a pharmaceutically acceptable salt thereof; or a combination as claimed in any one of claims 36 and 37; and - at least one pharmaceutically acceptable excipient.
39. The method of claim 38, wherein the pharmaceutical composition is administered orally or parenterally.
40. The method of any one of claims 29-39, wherein the dystrophinopathy is selected from Duchenne muscular dystrophy, Becker muscular dystrophy, Duchenne muscular dystrophy-associated dilated cardiomyopathy, or cramps with myoglobinuria.
41. The method of any one of claims 29-40, wherein the dystrophinopathy is Duchenne muscular dystrophy.
42. The method of any one of claims 29-41, wherein the patient is a pediatric subject.
